Articles

  • Sep 26, 2024 | asia.nikkei.com | Jun Watanabe

    TOKYO -- Japan's three megabanks plan to invest up to 5 billion yen ($35 million) each in Japanese chipmaker Rapidus, which aims to mass-produce cutting-edge semiconductors, Nikkei has learned. The government-backed Development Bank of Japan will also contribute 10 billion yen, bringing the major banks' total capital contribution to 25 billion yen ($175 million). The aim is to secure the funds needed for investment, and to stabilize cash flows ahead of the start of mass production in 2027.

  • Sep 16, 2024 | nature.com | Yoshiaki Nakamura |Jun Watanabe |Naoya Akazawa |Kozo Kataoka |Yoshinori Kagawa |Kun-Huei Yeh | +10 more

    AbstractThe interim analysis of the CIRCULATE-Japan GALAXY observational study demonstrated the association of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection with recurrence risk and benefit from adjuvant chemotherapy (ACT) in resectable colorectal cancer (CRC).

  • Jun 16, 2024 | asia.nikkei.com | Ryo Mukano |Jun Watanabe

    TOKYO -- Japanese memory chip maker Kioxia Holdings has ended production cuts after 20 months in light of a recovering market, with lenders agreeing to a new line of credit, Nikkei has learned. Kioxia in June raised operating rates on production lines back to 100% at its Yokkaichi plant, in Mie prefecture, and at its Kitakami plant, in Iwate prefecture. Both produce NAND flash memory.

  • May 8, 2024 | asia.nikkei.com | Sei Matsumoto |Jun Watanabe

    TOKYO -- Nissan Motor will extend financial support to an auto parts manufacturer that was once part of its affiliated supplier network but struggled to recover after the carmaker spread out its supply chain, Nikkei has learned. Nissan will provide 6 billion yen ($38.6 million) to Kasai Kogyo through a placement of a special class of shares with reduced voting rights. The Japanese automaker does not intend to make Kasai Kogyo a subsidiary.

  • Mar 14, 2024 | nature.com | Yoshinori Kagawa |J. Joshua Smith |Emmanouil Fokas |Jun Watanabe |Florian R. Greten |Hideaki Bando | +3 more

    AbstractDespite therapeutic advancements, disease-free survival and overall survival of patients with locally advanced rectal cancer have not improved in most trials as a result of distant metastases. For treatment decision-making, both long-term oncologic outcomes and impact on quality-of-life indices should be considered (for example, bowel function).

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →